Premium
Clinical comparison of methylprednisolone aceponate and prednicarbate in chronic eczema
Author(s) -
Albrecht G.
Publication year - 1994
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/j.1468-3083.1994.tb01063.x
Subject(s) - medicine , tolerability , methylprednisolone , adverse effect , clinical trial , dermatology , randomized controlled trial , clinical efficacy , surgery
Methylprednisolone aceponate (MPA) is a new topical corticosteroid developed specifically for the treatment of eczematous disorders. A multicentre, controlled, randomized open trial to assess the efficacy and tolerability of a once daily application of MPA in comparison to a twice‐daily application of Prednicarbate (PC) was conducted in 566 patients suffering from allergic contact eczema (51.2%), toxic degenerative eczema (46.8%) as well as a combination of allergic contact eczema and toxic degenerative eczema (1,9%). Both treatment groups were approximately the same size, 280 patients being treated with MPA, 286 with PC. Treatment was carried out for a maximum of 28 days. The median duration of treatment was 22 days with MPA and 21 days with PC. Clinical efficacy was not different between MPA ointment (0.1%) used once daily with 45.5% complete healing and 39.8% marked improvement as compared to PC ointment (0.25%) used twice daily with 48.3% complete healing and 40.2% marked improvement. Both treatments were well tolerated. 4.6% of the patients reported adverse events on MPA‐treatment and 3.8% on PC‐treatment. No serious events were experienced. From this study it can be concluded that in various eczematous disorders efficacy and tolerability of MPA ointment used once daily are essentially the same as for PC ointment used twice daily.